NantKwest

NantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease. It is a biotechnology company, engages in developing immunotherapeutic agents for various clinical conditions in the United States. The company’s product candidates include activated natural killer candidates for the treatment of virally-induced cancers, such as human papilloma virus-induced cervical, and head and neck cancers; ebola; and serious viral, fungal, and bacterial infections, as well as that is in Phase II clinical trials for the treatment of polyoma virus-induced merkel cell carcinoma.

NantKwest, established in 2002 and headquartered in United States, North America., specializes in Early Stage Venture investments across Biotechnology, Health Care, Pharmaceutical, Medical, Biopharma, Therapeutics, Oncology, Financial Services, Venture Capital, Finance. The organization boasts a portfolio of 1 investments, with an average round size of $18.4M and 1 successful exits. Their recent investments include Viracta Therapeutics, Latterell Venture Partners, Forward Ventures. The highest investment round they participated in was $809.6M. Among their most notable exits are Viracta Therapeutics and Latterell Venture Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.